Penta Pharma Profile
Key Indicators
- Authorised Capital ₹ 2.00 Cr
as on 01-07-2024
- Paid Up Capital ₹ 1.99 Cr
as on 01-07-2024
- Company Age 33 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 13.97 Cr
as on 01-07-2024
- Revenue 0.49%
(FY 2023)
- Profit -19.49%
(FY 2023)
- Ebitda 15.36%
(FY 2023)
- Net Worth 0.22%
(FY 2023)
- Total Assets 14.08%
(FY 2023)
About Penta Pharma
The Company is engaged in the Agriculture Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.00 Cr and a paid-up capital of Rs 1.99 Cr.
The company currently has active open charges totaling ₹13.97 Cr.
Padma Maheshwari, Shikhar Maheshwari, and Rajeev Maheshwari serve as directors at the Company.
- CIN/LLPIN
U24231UP1991PTC013617
- Company No.
013617
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
17 Oct 1991
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Kanpur
Industry
Company Details
- Location
Kanpur Dehat, Uttar Pradesh, India
- Telephone
- Email Address
- Website
- Social Media
Who are the key members and board of directors at Penta Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rajeev Maheshwari  | Managing Director | 17-Oct-1991 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Padma Maheshwari | Director | 20-Feb-2018 | Current |
| Shikhar Maheshwari | Director | 20-Feb-2018 | Current |
Financial Performance of Penta Pharma.
Penta Pharma Private Limited, for the financial year ended 2023, experienced modest growth in revenue, with a 0.49% increase. The company also saw a substantial fall in profitability, with a 19.49% decrease in profit. The company's net worth moved up by a moderate rise of 0.22%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Penta Pharma?
In 2023, Penta Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 25 Jan 2024 | ₹5.00 Cr | Open |
Bank Of India Creation Date: 12 Mar 2022 | ₹1.00 M | Open |
Bank Of India Creation Date: 12 Mar 2022 | ₹1.00 M | Open |
How Many Employees Work at Penta Pharma?
Penta Pharma has a workforce of 38 employees as of Mar 29, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Penta Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Penta Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
